Eris Lifesciences plans to lead in generic semaglutide drugs. The patent for Novo Nordisk's drug expires in India in March 2026. Eris aims for a significant market share. Several Indian drugmakers are also preparing to launch generic versions. Eris has experience with diabetes drugs. The company hopes to leverage its existing portfolio. It includes orals, insulin, and GLP-1.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0wQPGY2
via IFTTT
No comments:
Post a Comment